- Home
- XFOR vs INCR Comparison
XFOR vs INCR Comparison
Compare XFOR & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- INCR
- Stock Information
- Founded
- XFOR 2014
- INCR 1994
- Country
- XFOR United States
- INCR Israel
- Employees
- XFOR N/A
- INCR N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- INCR Health Care
- Exchange
- XFOR Nasdaq
- INCR Nasdaq
- Market Cap
- XFOR 84.3M
- INCR 82.3M
- IPO Year
- XFOR N/A
- INCR N/A
- Fundamental
- Price
- XFOR $3.81
- INCR $1.44
- Analyst Decision
- XFOR Strong Buy
- INCR
- Analyst Count
- XFOR 3
- INCR 0
- Target Price
- XFOR $34.17
- INCR N/A
- AVG Volume (30 Days)
- XFOR 1.4M
- INCR 40.0K
- Earning Date
- XFOR 11-12-2025
- INCR 10-08-2025
- Dividend Yield
- XFOR N/A
- INCR N/A
- EPS Growth
- XFOR N/A
- INCR N/A
- EPS
- XFOR N/A
- INCR N/A
- Revenue
- XFOR $32,774,000.00
- INCR $72,158,312.00
- Revenue This Year
- XFOR $1,307.51
- INCR $69.54
- Revenue Next Year
- XFOR N/A
- INCR $41.75
- P/E Ratio
- XFOR N/A
- INCR N/A
- Revenue Growth
- XFOR 5721.31
- INCR N/A
- 52 Week Low
- XFOR $1.35
- INCR $1.17
- 52 Week High
- XFOR $26.83
- INCR $1.80
- Technical
- Relative Strength Index (RSI)
- XFOR 62.18
- INCR 41.11
- Support Level
- XFOR $2.96
- INCR $1.42
- Resistance Level
- XFOR $4.54
- INCR $1.52
- Average True Range (ATR)
- XFOR 0.27
- INCR 0.07
- MACD
- XFOR 0.07
- INCR -0.01
- Stochastic Oscillator
- XFOR 55.75
- INCR 19.23
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.